Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Estimating the Chances of Older AML Patients to Achieve a Complete Remission Upon Intensive Induction Chemotherapy - An AMLCG and SAL Study

Utz O Krug, MD, Christian Rohde, Ph.D., Achim Heinecke, Ph.D., Maria Cristina Sauerland, Anja Koschmieder, Christoph Röllig, Markus Schaich, MD, Christian Thiede, Michael Kramer, Jan Braess, M.D., Karsten Spiekermann, MD, Torsten Haferlach, MD, Claudia Haferlach, MD, Gerhard Ehninger, Prof., Bernhard Josef Woermann, MD, Wolfgang E. Berdel, Wolfgang Hiddemann, MD, Thomas Buchner, Carsten Müller-Tidow

Blood (2010) 116 (21): 2696.

https://doi.org/10.1182/blood.V116.21.2696.2696

Published: 2010

Journal Articles

Addition of 5-Azacitidine to Standard Induction Therapy Is Feasible In Older Patients with Acute Myeloid Leukemia: The AML-AZA Trial of the SAL Study Group

Utz O Krug, MD, Anja Koschmieder, Joachim Gerss, PhD, Hubert Serve, MD, Björn Steffen, MD, Gesine Bug, MD, Markus Schaich, MD, Christian Brandts, MD, Christoph Röllig, MD, Gerhard Ehninger, MD, Ulrich Duehrsen, MD, Richard Noppeney, MD, Wolfgang E. Berdel, MD, Steffen Koschmieder, MD, Carsten Müller-Tidow, MD

Blood (2010) 116 (21): 2180.

https://doi.org/10.1182/blood.V116.21.2180.2180

Published: 2010

Journal Articles

Induction Therapy by Ara-C Plus Daunorubicin Versus Ara-C Plus Gemtuzumab Ozogamicin: Interim Analysis of a Randomized Phase II Trial of the SAL In Elderly Patients with Acute Myeloid Leukemia

Uta Brunnberg, Michael Mohr, Richard Noppeney, Heinz A. Duerk, Maria Cristina Sauerland, Carsten Müller-Tidow, Utz O Krug, Steffen Koschmieder, Torsten Kessler, Rolf M. Mesters, Christiane Schulz, Thomas Buchner, Gerhard Ehninger, Ulrich Dührsen, Hubert Serve, Wolfgang E. Berdel

Blood (2010) 116 (21): 335.

https://doi.org/10.1182/blood.V116.21.335.335

Published: 2010

Journal Articles

CCAAT/Enhancer Binding Protein Epsilon Mediates Nicotinamide-Enhanced Clearance of Staphylococcus Aureus Infection

Nils H. Thoennissen, MD, Pierre Kyme, Ching Wen Tseng, Gabriela B. Iwanski, Kenichi Shimada, Utz O Krug, MD, Adrian Gombart, PhD, H. Phillip Koeffler, MD, George Y. Liu

Blood (2010) 116 (21): 925.

https://doi.org/10.1182/blood.V116.21.925.925

Published: 2010

Journal Articles

Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome–negative myeloproliferative neoplasms

Blood (2010) 115 (14): 2882–2890.

https://doi.org/10.1182/blood-2009-07-235119

Published: 2010

Includes: Supplemental data

Journal Articles

A Phase II Multicentre Study with Elacytarabine as Second Salvage Therapy in Patients with AML.

Susan O'Brien, M.D., David A. Rizzieri, MD, Norbert Vey, Farhad Ravandi, Utz O. Krug, Mikkael A. Sekeres, MD, MS, Mike Dennis, Adriano Venditti, MD, Tove Flem Jacobsen, Karin Staudacher, Bo I Nilsson, MD, PhD, Francis J. Giles, MB, MD, FRCPI, FRCPath

Blood (2009) 114 (22): 1042.

https://doi.org/10.1182/blood.V114.22.1042.1042

Published: 2009

Journal Articles

Follow-up Analysis of a Randomized Comparison of Prolonged Myelosuppressive Maintenance Therapy Versus Intensive Consolidation Therapy as Postremission Therapy in AML.

Utz O. Krug, MD, Maria Cristina Sauerland, PhD, Bernhard J Woermann, MD, Wolfgang Berdel, MD, Wolfgang Hiddemann, MD, Thomas Buchner, MD

Blood (2009) 114 (22): 1056.

https://doi.org/10.1182/blood.V114.22.1056.1056

Published: 2009

Journal Articles

Prevalence and Prognostic Impact of Allelic Imbalances Associated with Leukemic Transformation of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.

Blood (2009) 114 (22): 1280.

https://doi.org/10.1182/blood.V114.22.1280.1280

Published: 2009

Journal Articles

Continuous Decrease of Overall Survival in Patients > 30 Years of Age with Acute Myelogenous Leukemia.

Utz O. Krug, MD, Wolfgang Berdel, MD, Susanne Amler, Maria C. Sauerland, PhD, Bernhard Wörmann, MD, Wolfgang Hiddemann, MD, Thomas Buchner, MD

Blood (2009) 114 (22): 998.

https://doi.org/10.1182/blood.V114.22.998.998

Published: 2009

Journal Articles

Loss of Structural Maintenance of Chromosomes 1A Protein Expression Is Associated with a Poor Prognosis in Acute Myelogenous Leukemia.

Utz O. Krug, MD, Claudia Hömme, PhD, Nicola Tidow, PhD, Horst Buerger, MD, Gabriele Koehler, MD, Achim Heinecke, PhD, Thomas Buchner, MD, Wolfgang E Berdel, MD, Steffen Koschmieder, MD, Carsten Mueller-Tidow, MD

Blood (2009) 114 (22): 4693.

https://doi.org/10.1182/blood.V114.22.4693.4693

Published: 2009

Journal Articles

A Novel Risk Score Predicts the Likelihood of a Complete Remission After Intensive Induction Therapy in Older AML Patients.

Utz O. Krug, MD, Achim Heinecke, PhD, Anja Koschmieder, MD, Matthias Stelljes, MD, Maria Cristina Sauerland, PhD, Wolfgang E Berdel, MD, Bernhard J Woermann, MD, Wolfgang Hiddemann, MD, Thomas Buchner, MD, Carsten Müller-Tidow, MD

Blood (2009) 114 (22): 327.

https://doi.org/10.1182/blood.V114.22.327.327

Published: 2009

Journal Articles

Long-Term Results in Patients with Acute Myeloid Leukemia (AML): The Influence of High-Dose AraC, G-CSF Priming, Autologous Transplantation, Prolonged Maintenance, Age, History, Cytogenetics, and Mutation Status. Data of the AMLCG 1999 Trial.

Blood (2009) 114 (22): 485.

https://doi.org/10.1182/blood.V114.22.485.485

Published: 2009

Journal Articles

Older Age Is An Independent Risk Factor in AML

Blood (2008) 112 (11): 555.

https://doi.org/10.1182/blood.V112.11.555.555

Published: 2008

Journal Articles

Prolonged Monthly Myelosuppressive Maintenance Chemotherapy in Acute Myeloid Leukemia: The AMLCG Experience.

Utz O. Krug, MD, Wolfgang E. Berdel, MD, Maria Cristina Sauerland, Achim Heinecke, PhD, Bernhard Josef Wormann, MD, Wolfgang Hiddemann, MD, Thomas Buchner, MD

Blood (2007) 110 (11): 1856.

https://doi.org/10.1182/blood.V110.11.1856.1856

Published: 2007

Journal Articles

The Outcome in AML Is Predicted by Cytogenetics, NPM1/FLT3 Mutation, Age and Sex, but Not by Treatment Variables.

Thomas Buchner, Wolfgang E. Berdel, Utz O. Krug, Torsten Haferlach, Claudia Haferlach, Susanne Schnittger, Wolfgang Kern, Carsten Müller-Tidow, Karsten Spiekermann, Jan Braess, Sarah Volpert, Maria Cristina Sauerland, Achim Heinecke, Bernhard Josef Wormann, Wolfgang Hiddemann

Blood (2007) 110 (11): 593.

https://doi.org/10.1182/blood.V110.11.593.593

Published: 2007

NARROW

Estimating the Chances of Older AML Patients to Achieve a Complete Remission Upon Intensive Induction Chemotherapy - An AMLCG and SAL Study

Addition of 5-Azacitidine to Standard Induction Therapy Is Feasible In Older Patients with Acute Myeloid Leukemia: The AML-AZA Trial of the SAL Study Group

Induction Therapy by Ara-C Plus Daunorubicin Versus Ara-C Plus Gemtuzumab Ozogamicin: Interim Analysis of a Randomized Phase II Trial of the SAL In Elderly Patients with Acute Myeloid Leukemia

CCAAT/Enhancer Binding Protein Epsilon Mediates Nicotinamide-Enhanced Clearance of Staphylococcus Aureus Infection

Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome–negative myeloproliferative neoplasms

A Phase II Multicentre Study with Elacytarabine as Second Salvage Therapy in Patients with AML.

Follow-up Analysis of a Randomized Comparison of Prolonged Myelosuppressive Maintenance Therapy Versus Intensive Consolidation Therapy as Postremission Therapy in AML.

Prevalence and Prognostic Impact of Allelic Imbalances Associated with Leukemic Transformation of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.

Continuous Decrease of Overall Survival in Patients > 30 Years of Age with Acute Myelogenous Leukemia.

Loss of Structural Maintenance of Chromosomes 1A Protein Expression Is Associated with a Poor Prognosis in Acute Myelogenous Leukemia.

A Novel Risk Score Predicts the Likelihood of a Complete Remission After Intensive Induction Therapy in Older AML Patients.

Long-Term Results in Patients with Acute Myeloid Leukemia (AML): The Influence of High-Dose AraC, G-CSF Priming, Autologous Transplantation, Prolonged Maintenance, Age, History, Cytogenetics, and Mutation Status. Data of the AMLCG 1999 Trial.

Older Age Is An Independent Risk Factor in AML

Prolonged Monthly Myelosuppressive Maintenance Chemotherapy in Acute Myeloid Leukemia: The AMLCG Experience.

The Outcome in AML Is Predicted by Cytogenetics, NPM1/FLT3 Mutation, Age and Sex, but Not by Treatment Variables.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only